Yalcin, Suayib
Dane, Faysal
Oksuzoglu, Berna
Ozdemir, Nuriye Yildirim
Isikdogan, Abdurrahman
Ozkan, Metin
Demirag, Guzin Gonullu
Coskun, Hasan Senol
Karabulut, Bulent
Evrensel, Turkkan
Ustaoglu, Mehmet Ali
Ozdemir, Feyyaz
Turna, Hande
Yavuzsen, Tugba
Aykan, Faruk
Sevinc, Alper
Akbulut, Hakan
Yuce, Deniz
Hayran, Mutlu
Kilickap, Saadettin
Funding for this research was provided by:
Türk Tıbbi Onkoloji Derneği (wwww)
Türk Kanser Araştirma ve Savaş Kurumu Derneği (awe)
hacettepe onkoloji derneği (wwww)
Celgene (aaaa)
onkoloji araştırmaları derneği (aaa)
Article History
Received: 16 March 2019
Accepted: 17 March 2020
First Online: 30 March 2020
Ethics approval and consent to participate
: This study was approved by the Malatya Clinical Trials Ethics Committee of Inonu University. Approval date was 21 May 2014, and approval number was 2014/58.Written informed consent was obtained from all patients.
: Not applicable
: <b>SY:</b> Honorarium due to advisory board activity, speaker, bureau activity from Roche, Novartis, Amgen, Gen Ilac, Merck Serono, Pfizer, Lilly, Sanofi, MSD, BMS, Teva, Celgene Abbott, and Bayer.